B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GABRB2

MOLECULAR TARGET

gamma-aminobutyric acid type A receptor subunit beta2

UniProt: P47870NCBI Gene: 256113 compounds

GABRB2 (gamma-aminobutyric acid type A receptor subunit beta2) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GABRB2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gamma-Aminobutyric Acid3.8144
2Pregnanolone2.087
3Etomidate Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or1.795
4Apigenin 5,7,4'-trihydroxy-flavone,1.102
5chrysin1.102
6Androsterone1.102
7Bicuculline1.102
8Eszopiclone1.102
9Ciprofloxacin0.691
10Etiocholanolone0.691
11Ondansetron0.691
12Picrotoxin0.691
13Triiodothyronine0.691

About GABRB2 as a Drug Target

GABRB2 (gamma-aminobutyric acid type A receptor subunit beta2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented GABRB2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GABRB2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.